On Monday, in the course of Afternoon trade, Shares of VIVUS, Inc. (NASDAQ:VVUS), dropped -3.97%, and is now trading at $1.45.
VIVUS, offered a business update, stated its financial results for the second quarter ended June 30, 2015 and declared a restructuring plan.
“The U.S. market for branded anti-obesity pharmacotherapeutics has developed at a substantially lower rate than predictable, held in check by a number of factors,” said Seth H. Z. Fischer, CEO. “As stated formerly, we have watched this trend closely while controlling our costs throughout the first half of 2015, and we have undertaken a further review of all aspects of the Company’s operations. In order to reallocate resources most efficiently in support of Qsymia and other projects, VIVUS is announcing, effective right away, a corporate restructuring that will reduce headcount and expenses with an objective of achieving neutral or positive operating cash flows by year-end 2016. We will be reducing our Qsymia sales force to fifty territories and streamlining further our headquarters staff. We believe that this cost-saving restructuring is timely, prudent and compriseent with evolving obesity market realities and the opportunity as it presently exists. Going forward, we will continue to monitor market conditions for any positive developments with physicians, payors, and patients that may indicate an raised investment is warranted.”
VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health in the United States and the European Union.
During an Afternoon trade, Shares of TAL International Group, Inc. (NYSE:TAL), climbed 6.16%, and is now trading at $21.02.
TAL International Group, declared that it will report its financial results for the second quarter ended June 30, 2015 after the market closes on Wednesday, July 29, 2015. The Company’s administration will host a conference call on Thursday, July 30, 2015 at 9:00 a.m. ET to review the second quarter financial results.
The conference call will be Webcast, and an archive of the Webcast will be accessible one hour after the live call through Friday, September 11, 2015.
TAL International Group, Inc., together with its auxiliaries, leases intermodal transportation equipment and provides maritime container administration services worldwide. The company operates in two segments, Equipment Leasing and Equipment Trading.
Shares of Express Scripts Holding Company (NASDAQ:ESRX), during its Monday’s current trading session fell -1.69%, and is now trading at $88.73.
Express Scripts Holding Company, declared 2015 second quarter net income attributable to Express Scripts stockholders of $600.1 million, or $0.88 per diluted share. Adjusted earnings per diluted share, as detailed in Table 4, were $1.44 for the second quarter.
“It is clear many companies across healthcare are validating the need for size and scale,” said George Paz, Chairman and Chief Executive Officer. “But, what matters most is how that size and scale is leveraged. In our case, that means creating a business model fully aligned with client needs. By aligning our interests with those of our patients and clients our scale is focused on driving down costs while improving health outcomes. Our focused size and scale assists us make prescription drugs safer and more affordable which benefits everyone in healthcare — patients, plan sponsors and medical professionals. We are happy with our second quarter results and outperforming our guidance. Our results are a testament to our model of driving performance through our focused scale and alignment.”
Express Scripts Holding Company operates as a pharmacy benefit administration (PBM) company in the United States and Canada. The company operates through two segments, PBM and Other Business Operations.
Finally, KLA-Tencor Corp (NASDAQ:KLAC), lost -1.00% Monday.
KLA-Tencor Corporation, declared operating results for its fourth quarter and fiscal year ended June 30, 2015. KLA-Tencor stated GAAP net income of $142 million and GAAP earnings per diluted share of $0.89 on revenues of $756 million for the fourth quarter of fiscal year 2015. For the fiscal year ended June 30, 2015, the company stated GAAP net income of $366 million and GAAP earnings per diluted share of $2.24 on revenues of $2.8 billion.
“KLA-Tencor posted solid results for the fourth quarter of fiscal year 2015, delivering earnings near the top of our range of guidance, demonstrating our market leadership and strong operational execution,” said Rick Wallace, President and Chief Executive Officer. “KLA-Tencor’s advanced process control solutions and services play an enabling role in assisting our customers achieve their growth strategies in leading edge semiconductor device manufacturing.”
KLA-Tencor Corporation designs, manufactures, and markets process control and yield administration solutions worldwide. It provides chip manufacturing products, counting front-end defect inspection, back-end defect inspection, defect review, metrology, and in-situ process monitoring products, in addition to lithography modeling software; wafer manufacturing products comprising surface and defect inspection, wafer geometry and nanotopography metrology, and data administration; and reticle manufacturing products, such as defect inspection and pattern placement metrology products.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
